Smoking and Nicotine

Combustible tobacco is biologically incompatible with longevity — and the harm is partly reversible after quitting. Vapes and oral nicotine pouches eliminate the smoke but introduce their own cardiovascular and addiction risks. Low-dose isolated nicotine has produced a striking NAD+/longevity signal in mice that has not yet been tested in healthy humans.

The smoking question split into two questions once non-combustible nicotine products spread: what does the smoke do, and what does the nicotine do? For combustible cigarettes the answer is unambiguous and the largest preventable-mortality lever in modern medicine. For e-cigarettes and oral pouches, harm reduction relative to smoking is real, but "less than cigarettes" is a low bar — they carry their own endothelial, addiction, and (for pouches) cardiovascular signals. For isolated low-dose nicotine in the transdermal-patch format, the human cardiovascular data look benign, the acute cognitive benefits are well-documented, and recent mouse work hints at an NAD+/SIRT1 longevity pathway that has not been validated in humans.

What the evidence says

Strong:

Tobacco smoking is the leading preventable cause of death worldwide — ~8 million deaths a year, with ~1.2 million attributed to second-hand exposure^[1].
Smoking accelerates epigenetic age across multiple respiratory tissues — airway epithelium by ~4.9 years and lung parenchyma by ~4.3 years on average versus age-matched non-smokers^[2].
Cumulative lifetime smoking exposure (pack-years, parental smoking, youth initiation) accelerates the GrimAge clock in older adults and predicts all-cause mortality on top of that^[3].
Leukocyte telomeres shorten faster in smokers — 84-study meta-analysis with consistent dose-response^[4].
Cigarette smoking impairs skeletal-muscle protein synthesis and upregulates myostatin (+33%) and the atrophy ligase MAFbx (+45%), driving early sarcopenia^[5].
Young adult smokers have ~2.4× the metabolic-syndrome risk of non-smoking peers, with 2.6× higher hypertriglyceridemia and 3× higher rates of low HDL^[6].
Cessation reduces epigenetic-age acceleration in superficial airway tissue back toward never-smoker rates; deep lung parenchyma retains its accelerated profile^[7].
Quitting smoking at any age improves cognitive trajectory; adults who quit a decade or more before late-life assessment have dementia risk indistinguishable from never-smokers^[8].

Moderate:

Acute isolated nicotine (gum, patch) improves sustained attention, working memory, and inhibitory control in healthy non-smokers in dozens of double-blind trials^[9].
E-cigarette use raises resting heart rate (~+1.4 bpm) and both systolic and diastolic blood pressure; induces endothelial dysfunction and is epidemiologically associated with elevated coronary heart disease, stroke, and heart-failure risk^[10].
Transdermal nicotine in non-smokers and in mildly hypertensive cardiac patients shows no measurable excess risk of arrhythmia, myocardial infarction, or stroke across pooled RCTs — the safest delivery profile currently available^[11].
Adolescent cotinine-confirmed second-hand smoke exposure associates with ~4.7× metabolic-syndrome odds^[12].
The cardiovascular risk profile of oral nicotine pouches (ZYN and competitors) is essentially unstudied long-term despite a ~10× US sales increase 2019–2022 — sympathetic spikes are documented; durable hemodynamic and addiction effects are not^[13].

Weak / preliminary:

Low-dose nicotine (2 µg/mL in drinking water, 6 → 12 months) restored NAMPT activity, raised NAD+, preserved motor and exploratory behavior, and stabilized telomere-associated TPP1/RAP1 ratios in aged male mice — via SIRT1-mediated deacetylation of NAMPT, independent of nicotinic acetylcholine receptors^[14]. Mouse data only; no human trial of nicotine as an NAD+ booster yet.
Modest, narrow ergogenic effects in fine motor control and reaction time; no consistent improvement in maximal strength, endurance, or VO₂^[15].

Caution:

Adolescent nicotine exposure permanently reduces hippocampal CA1 dendritic length and predisposes to adult depression and learning deficits in rodent models, mirroring elevated relapse and cognitive-deficit signals in humans who started smoking young^[16].
Nicotine plus heavy exercise in heat blunts cutaneous vasodilation and impairs thermoregulation, raising heat-illness risk in endurance athletes^[17].
High-pH oral pouches (median pH ~8.8, up to 47 mg nicotine per pouch) drive very rapid blood nicotine spikes; addiction liability is high and the long-term cardiovascular profile is unknown.

Cellular and epigenetic aging

Smoking is among the most consistent accelerators of biological-aging biomarkers ever measured. The signal shows up across:

Epigenetic clocks. DNA-methylation signatures in airway, lung, esophagus, and buccal cells of smokers run several years older than chronological age. GrimAge and DunedinPACE pick this up systemically; per-standard-deviation cotinine increments translate to ~1.4 years of GrimAge2 acceleration in NHANES analyses (see also environmental toxins).
Telomere attrition. Smoking lowers expression of shelterin components (TRF2, POT1) and the catalytic telomerase subunit hTERT in blood and buccal samples, accelerating chromosomal-end degradation and replicative senescence.
Autophagy and SIRT1. Cigarette smoke extract suppresses SIRT1, activates PARP-1, and tips the airway and lung into pathological autophagic flux and senescence — the molecular substrate for COPD.

The most actionable finding from this body of work is that cessation partially reverses the epigenetic-aging signal in superficial airway tissue but not in deep lung parenchyma. The longer the active exposure, the more parenchymal scarring is preserved. This is consistent with the long-running cohort observation that the all-cause-mortality benefit of quitting accumulates over years and never quite reaches never-smoker rates for very heavy smokers — but it gets close, especially for adults who quit before midlife.

Cognition: the acute–chronic split

The neurological evidence is bimodal. Acute, controlled isolated nicotine is a robust cognitive enhancer in healthy adults: sustained attention, working memory, fine motor performance, and inhibitory control (Stroop) all improve in repeated placebo-controlled trials of 7 mg transdermal patches. Mechanism is straightforward — nAChR activation triggers dopamine, acetylcholine, and glutamate release across cortex and basal ganglia. There's a specificity caveat: nicotine narrows attention onto focal stimuli at the expense of peripheral-orienting flexibility, which is why heavy users describe both "lock-in" focus and missing things in their environment.

Chronic combustible smoking does the opposite over years. High-resolution MRI of heavy smokers shows gray-matter atrophy in superior temporal gyrus, insula, precuneus, and posterior cingulate, extending into thalamus, putamen, and pallidum at higher exposure. Thalamic atrophy specifically correlates with the impulse-control failures that predict relapse — the brain physically loses the structure that supports quitting.

The longitudinal data are unambiguous. ELSA, SHARE, and HRS cohorts show smoking accelerates global cognitive decline; quitting at any age slows that trajectory, and a decade-plus of abstinence is enough to bring dementia risk back in line with never-smokers. For brain health specifically, the cessation signal is among the largest single modifiable levers — see Dementia prevention.

Muscle and exercise

Smoking is a strong driver of premature sarcopenia. Isotopic-tracer studies show fractional muscle-protein synthesis rates reduced in active smokers compared to matched non-smokers, with biopsy-confirmed +33% myostatin and +45% MAFbx expression — a targeted upregulation of the atrophy machinery rather than a generalized stress response. Nicotine alone contributes peripheral vasoconstriction that limits oxygen and amino-acid delivery to working muscle and slows recovery.

The ergogenic case for isolated nicotine in athletes is weaker than its popularity in elite sports would suggest. Across 16 physical-performance endpoints in systematic reviews, 12 show no significant effect; the remaining four are narrow improvements in reaction time and fine-motor tasks (e.g., pegboard, baseball-batting timing). No published trial has shown an increase in maximum strength or maximum aerobic capacity. The withdrawal window is also relevant: in the first 12–24 hours after cessation, attention and reaction time drop measurably; beyond 48 hours, a rebound improvement appears.

Two underappreciated cautions for athletes: nicotine reduces skin blood flow and blunts the thermoregulatory response to heavy exercise in heat (a recognised risk by WADA); and combining nicotine with a high-fat diet drives intramyocellular lipid accumulation and mitochondrial abnormalities in muscle that don't occur with the high-fat diet alone.

Metabolic effects

The acute appetite-suppressing, weight-modulating effect of nicotine — long the marketing rationale for its non-medical use — comes from α-adrenoceptor-driven catecholamine release and a transient drop in fasting glucose. Chronically, the picture inverts: nicotine is toxic to pancreatic β-cells in animal models, drives insulin resistance, and predisposes to metabolic syndrome and type 2 diabetes in human cohorts, with effect sizes that survive years after quitting. The Fagerström-dependence score correlates linearly with the TyG insulin-resistance index — addiction severity tracks metabolic damage.

This is one of the reasons "vaping for weight loss" is a strictly worse trade than the alternative interventions discussed under Metabolic flexibility and the prescription GLP-1 receptor agonists.

Delivery systems: not interchangeable

Delivery vector	Cardiovascular	Respiratory	Key toxicants & risks
Combustible cigarettes	Severe atherosclerosis, thrombosis, large MI/stroke risk	Irreversible COPD, emphysema, ~85% of lung cancers	7,000+ chemicals incl. tar, CO, polycyclic aromatic hydrocarbons, cadmium
E-cigarettes (ENDS)	Endothelial dysfunction; +1.4 bpm HR, BP elevations; coronary disease and stroke signals in cohorts	Reduced lung function; asthma odds ~1.3×; rare but lethal EVALI	Aldehydes (formaldehyde from coil-heated propylene glycol), heavy metals (Ni, Pb, Cr) from coils
Oral pouches (e.g., ZYN)	Acute sympathetic spikes; long-term CV outcomes unstudied	Negligible direct respiratory load	High pH (~8.8) maximizes free-base bioavailability; 1–47 mg/pouch; addiction-prone; trace nitrosamines possible
Transdermal patch	Transient mild HR/BP rise; no measurable MI/stroke excess in RCTs	None	Steady-state pharmacokinetics; cleanest CV profile currently in clinical use

The "harm-reduction" hierarchy these data support: combustible >> ENDS ≥ pouches >> transdermal patch. None of this validates ENDS or pouches as long-term recreational products in healthy adults — the absence of decades of cohort data is doing a lot of the work for them, and the cardiovascular signals already emerging are real.

The low-dose nicotine paradox

The most interesting recent finding is a mouse study that should not be over-interpreted. Aged male mice (6 → 12 months) given low-dose nicotine in drinking water (2 µg/mL) showed:

Restored NAMPT activity in brain, liver, and pancreas;
Increased β-NMN (a direct NAD+ precursor) and systemic NAD+;
Preserved exploratory behavior and motor function characteristic of younger animals;
Suppressed pathological glucose hypermetabolism on FDG-PET;
Increased TPP1 and decreased RAP1 in aged tissues, stabilizing telomere-associated complexes.

The mechanism is specific: nicotine physically facilitates the binding of SIRT1 to NAMPT, allowing SIRT1 to deacetylate and activate NAMPT, which feeds back into the NAD+ salvage pathway. The action does not extend to SIRT1's other substrates (p53, NF-κB, PGC-1α) and is independent of the classical nicotinic acetylcholine receptors. In effect, the molecule may behave like a non-canonical NAD+ booster on a small subset of SIRT1 substrates.

What this is not, yet: a human longevity intervention. There is no human trial of low-dose nicotine for NAD+ repletion or epigenetic-clock deceleration. The mouse work and the well-studied cardiovascular safety of transdermal patches together motivate cautious interest, not a recommendation. Anyone with a history of nicotine addiction should treat experimental low-dose use with extreme skepticism — addiction biology is unforgiving.

For the current generation of NAD+ interventions actually supported by human data, see Geroprotectors.

Practical guidance

If you smoke combustibles, quitting is the single largest health intervention available to you. No other modifiable factor in this corpus has a comparable effect size on all-cause mortality. The cognitive- and lung-tissue-recovery data also argues against the "I've smoked too long for it to matter" framing — the recovery signal continues to accumulate for years.
Vapes are not "safe" — they're less bad than cigarettes. Defensible as a cessation tool with a planned exit. Not defensible as a long-term recreational habit, particularly in healthy adults with no smoking history.
Oral nicotine pouches deserve more skepticism than they currently receive. High-pH formulations maximize absorption and addiction potential; the cardiovascular profile is essentially unstudied. The youth uptake curve is alarming.
Nicotine and resistance training are working against each other. Anyone trying to build or preserve muscle mass should regard chronic nicotine use as a meaningful drag on the system.
Don't combine nicotine with hot-environment endurance exercise. The thermoregulatory impairment is real and the consequences are acute.
Adolescent exposure is in a different category. Both human and animal data suggest the developing brain takes permanent structural hits from chronic nicotine. Vaping marketed to teenagers is a public-health failure, not a harm-reduction success.
Low-dose nicotine as a longevity intervention is not yet evidence-based for humans. Watch the literature; do not act on mouse data.

What's overrated

"Vaping is safe." It's safer than combustible smoking. It is not without measurable cardiovascular and respiratory effects, and the long-cohort data are still arriving.
Nicotine as a sport-performance enhancer. Modest reaction-time effects only; no demonstrated improvement in strength or aerobic capacity; meaningful heat-stress risk.
Nicotine as an "NAD+ booster" in humans. Strong mouse signal; zero human longevity trials.
The historical claim that nicotine itself is comparable in harm to tobacco smoke. Combustion products do most of the cancer and cardiovascular damage; isolated nicotine has its own narrower risk profile.